Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: Audio-slides

Published: 11 February 2020| Version 1 | DOI: 10.17632/cj98sw6zr5.1
Contributors:
pierre van damme,
Geert Leroux-Roels,
Corinne Vandermeulen,
Iris De Ryck,
Annaelisa Tasciotti,
Marie Dozot,
Luca Moraschini,
Marco Testa,
Ashwani Kumar Arora

Description

These audio-slides support the published article Pierre Van Damme, Geert Leroux-Roels, Corinne Vandermeulen, Iris De Ryck, Annaelisa Tasciotti, Marie Dozot, Luca Moraschini, Marco Testa, Ashwani Kumar Arora. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. 2019;37(23):3113-3122. In this article, we provide evidence that an investigational non-typeable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) protein vaccine has an acceptable safety and reactogenicity profile and good immunogenicity in older adults with smoking history.

Files

Institutions

GlaxoSmithKline Biologicals SA

Categories

Vaccine, Chronic Obstructive Pulmonary Disease, Immunogenicity, Safety, Clinical Trial Results, Haemophilus influenzae, Exacerbation (Medicine)

License